Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial

Key Points

• To investigate the effectiveness of nintedanib in treating progressive bronchiolitis obliterans syndrome in lung transplant recipients.
• Conduct a multicenter randomized controlled trial.
• Include lung transplant patients diagnosed with bronchiolitis obliterans syndrome grade 0p-1-2.
• Administer nintedanib as the intervention.
• Use standardized assessment protocols for efficacy measurement.
• Anticipated improvement in clinical outcomes for patients treated with nintedanib.
• Comparison of treatment effectiveness across different grades of bronchiolitis obliterans syndrome.

Abstract